# Evommune, Inc. (EVMN)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $126M  
**Price:** $20.49

> Evommune, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for immune-mediated chronic inflammatory diseases. Founded in 2020 and headquartered in Palo Alto, California, Evommune aims to create innovative treatments that address major unmet medical needs in conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s product candidates, EVO756 and EVO301, are currently in Phase 2 clinical trials, targeting both symptomatic relief and the underlying drivers of chronic inflammation. By leveraging advanced scientific research and a seasoned management team with deep expertise in immunology and drug development, Evommune, Inc. is positioned to contribute meaningfully to the rapidly evolving biopharmaceutical landscape. As a publicly listed entity, the company provides investors access to a specialized segment of the healthcare sector, reflecting broader investor interest in innovative biotech firms addressing chronic disease burden.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $13M | — | -$81M | -$69M | $-11.22 |
| 2024 | $7M | — | -$70M | -$67M | $-45.29 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $225M | $19M | $206M | $44M | — |
| 2024 | $76M | $29M | -$144M | $16M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$76M | $235,000 | -$77M |
| 2024 | -$58M | $88,000 | -$58M |

Source: [CompaniesByCap](https://companiesbycap.com/company/EVMN)